Phone: (650) 368 6983 info@airmid.com

February 2011 February 2011 AIRMID partners with Circassia to develop topical PAP-1 January 2010 Joe Sum joins AIRMID Board of Directors July 2009 AIRMID partners with Kineta to develop ShK peptides more...   Airmid Incorporated George Miljanich PhD, CEO 600 Castle Hill Road Redwood City, CA 94061 gmiljanich@comcast.net 650-368-6983 650-269-7078   AIRMID is seeking a committed development partner for its promising autoimmune treatment, PAP-1 Oral MULTIPLE SCLEROSIS, psoriasis AND/OR TYPE 1 DIABETES drug SUPPOSITORY CROHN'S DISEASE drug

Home | Autoimmune disease | Multiple sclerosis | Type 1 diabetes mellitus | Kv1.3 Potassium Channel | PAP-1 | ShK Effector memory T cells | Contact | Sitemap Copyrights © 2007, www.airmid.com